Capmatinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 150 mg, 200 mg
Reference Brands: Tabrecta (USA/EU)
Category:
Oncology Cancer Care
Capmatinib is available in Tablets
and strengths such as 150 mg, 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Capmatinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Capmatinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Capmatinib is a targeted anticancer medication used for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a specific genetic alteration known as MET exon 14 skipping mutation. It belongs to the class of kinase inhibitors and works by selectively blocking the MET receptor tyrosine kinase (also known as hepatocyte growth factor receptor, HGFR), which plays a key role in tumor cell growth, survival, and spread when abnormally activated. By inhibiting this pathway, capmatinib helps slow cancer progression and reduce tumor activity in patients with MET-driven disease.
Capmatinib is prescribed only after confirmed molecular testing shows the presence of the MET exon 14 skipping mutation, making it a precision therapy aligned with biomarker-based treatment selection. Clinical studies have demonstrated meaningful response rates and durable tumor control in eligible patients. The medicine is marketed under the brand name Tabrecta and is used under oncology specialist supervision, with regular monitoring for safety and treatment response. It represents an important personalized treatment option in modern lung cancer care.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing